By Nigam Arora & Dr. Natasha Arora
UnitedHealth Group Incorporated (UNH) is the country’s largest health insurer. The stock has fallen about 16% to $318.70 as of this writing on the company’s suspension of guidance. As a reference, the 52 week high is $630.73.
The Arora Report proprietary indicators are showing a decent probability of the stock being close to the bottom.
Zones
The buy zone is $*** (To see the locked content, please take a 30 day free trial) – $*** to scale in.
The maximum recommended quantity is ***% of the full core position size. It is important to limit the quantity at this time.
The tentative plan is to buy more if the stock falls in the zone of $*** – $***.
This is a very long term position. The very long term target is $578 – $606 to scale out.
The mental stop zone is $*** – $***.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
